

Neu siRNA (h): sc-29405

BACKGROUND

The EGF receptor family comprises several related receptor tyrosine kinases that are frequently overexpressed in a variety of carcinomas. Members of this receptor family include EGFR (HER1), Neu (ErbB-2, HER2), ErbB-3 (HER3), and ErbB-4 (HER4), which form either homodimers or heterodimers upon ligand binding. Neu, a glycoprotein, undergoes transactivation upon heterodimerization with other EGF receptor family members. Neu heterodimerization with ErbB-3 recruits heregulin, which induces phosphoinositide (PI) 3-kinase activation. Activation of Neu potentiates tumor cell motility and protease secretion and invasion, and also modulates cell cycle checkpoint function, DNA repair and apoptotic responses. Amplification and/or overexpression of Neu occurs in 20-30% of breast carcinomas. Measurement of increased Neu expression can be a predictor of disease prognosis. Neu may also prove to be a promising target for therapeutic agents.

CHROMOSOMAL LOCATION

Genetic locus: ERBB2 (human) mapping to 17q12.

PRODUCT

Neu siRNA (h) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see Neu shRNA Plasmid (h): sc-29405-SH and Neu shRNA (h) Lentiviral Particles: sc-29405-V as alternate gene silencing products.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

Neu siRNA (h) is recommended for the inhibition of Neu expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.


GENE EXPRESSION MONITORING

Neu (3B5): sc-33684 is recommended as a control antibody for monitoring of Neu gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor Neu gene expression knockdown using RT-PCR Primer: Neu (h)-PR: sc-29405-PR (20 μ l, 425 bp). Annealing temperature for the primers should be 55-60 $^{\circ}$ C and the extension temperature should be 68-72 $^{\circ}$ C.

DATA



Neu siRNA (h): sc-29405. Western blot analysis of Neu expression in non-transfected control (A) and Neu siRNA transfected (B) A-431 cells. Blot probed with Neu (C-18): sc-284. α -actinin (H-2): sc-17829 used as specificity and loading control.

SELECT PRODUCT CITATIONS

- García-Morales, P., et al. 2006. Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells. *Mol. Cancer Ther.* 5: 2172-2181.
- Zhu, Y., et al. 2010. MicroRNA-21 is involved in ionizing radiation-promoted liver carcinogenesis. *Int. J. Clin. Exp. Med.* 3: 211-222.
- Li, Y.W., et al. 2011. Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells. *Cancer Chemother. Pharmacol.* 68: 1315-1323.
- Ma, S., et al. 2016. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. *Cell Death Dis.* 7: e2307.
- Shu, T., et al. 2017. Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment. *Cancer Lett.* 411: 65-73.
- Shin, D.H., et al. 2018. Dual targeting of ERBB2/ERBB3 for the treatment of SLC3A2-NRG1-mediated lung cancer. *Mol. Cancer Ther.* 17: 2024-2033.
- Aihara, Y., et al. 2019. Algal photoprotection is regulated by the E3 ligase CUL4-DDB1^{DET1}. *Nat. Plants* 5: 34-40.
- Liu, H., et al. 2021. Erb-B2 Receptor Tyrosine Kinase 2 is negatively regulated by the p53-responsive microRNA-3184-5p in cervical cancer cells. *Oncol. Rep.* 45: 95-106.

RESEARCH USE

For research use only, not for use in diagnostic procedures.